Early Izokibep (IL17Ai) data demonstrated clinically meaningful, dose-dependent improvement across PROs, particularly sleep, pain, function ,+ SF36 and PsAID subdomains in PsA pts. Pts w/ baseline enthesitis had greater benefit. Abs 0199 #ACR22 @RheumNow
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes - 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis - ACR Meeting Abstracts
